Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2023-08-03 Sale | 2023-08-07 9:17 pm | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 275,888 | $2.5151 | $693,897 | 15,521,248 (Direct) | View |
| 2023-08-01 Sale | 2023-08-03 8:31 pm | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 179,648 | $2.6437 | $474,938 | 15,797,136 (Direct) | View |
| 2023-05-01 Sale | 2023-05-03 7:48 pm | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 455,528 | $2.5759 | $1,173,395 | 15,976,784 (Direct) | View |
| 2023-02-01 Sale | 2023-02-03 6:19 pm | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 413,168 | $2.5572 | $1,056,553 | 16,432,312 (Direct) | View |
| 2022-12-20 Sale | 2022-12-21 4:05 pm | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 600,000 | $2.1151 | $1,269,060 | 16,845,480 (Direct) | View |
| 2022-11-01 Sale | 2022-11-03 4:05 pm | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 13,160 | $1.6726 | $22,011 | 17,445,480 (Direct) | View |
| 2022-08-09 Sale | 2022-08-11 9:45 pm | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 600,000 | $1.75 | $1,050,000 | 14,313,496 (Direct) | View |
| 2022-08-01 Sale | 2022-08-03 4:10 pm | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 13,168 | $0.6998 | $9,215 | 14,913,496 (Direct) | View |
| 2022-05-03 Sale | 2022-05-05 7:18 pm | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 12,512 | $0.4956 | $6,201 | 15,381,520 (Direct) | View |
| 2022-02-02 Sale | 2022-02-03 5:54 pm | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 10,416 | $0.7562 | $7,877 | 15,826,160 (Direct) | View |
| 2021-11-02 Sale | 2021-11-03 7:51 pm | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 10,416 | $0.6453 | $6,721 | 15,991,120 (Direct) | View |
| 2021-08-02 Sale | 2021-08-03 9:45 pm | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 10,416 | $0.767 | $7,989 | 16,456,384 (Direct) | View |
| 2021-05-03 Sale | 2021-05-05 4:06 pm | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 10,416 | $0.8731 | $9,094 | 16,921,640 (Direct) | View |
| 2021-03-01 Sale | 2021-03-03 8:05 pm | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 26,728 | $1.1438 | $30,571 | 19,054,504 (Direct) | View |
| 2019-09-30 Sale | 2019-10-02 4:20 pm | Dova Pharmaceuticals Inc. | DOVA | Hahn Mark W Chief Financial Officer | 775 | $28 | $21,700 | 9,024 (Direct) | View |
| 2019-07-01 Sale | 2019-07-02 4:59 pm | Dova Pharmaceuticals Inc. | DOVA | Hahn Mark W Chief Financial Officer | 1,545 | $14.17 | $21,893 | 9,799 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-05-01 Tax Withholding | 2024-05-03 7:23 pm | N/A N/A | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 88,544 | $1.9313 | 14,943,032 (Direct) | View |
| 2024-02-01 Tax Withholding | 2024-02-05 6:09 pm | N/A N/A | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 480,664 | $2.2938 | 15,031,576 (Direct) | View |
| 2023-11-01 Tax Withholding | 2023-11-03 8:08 pm | N/A N/A | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 809,008 | $1.7438 | 15,512,240 (Direct) | View |
| 2023-10-20 Option Award | 2023-10-24 4:05 pm | N/A N/A | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 800,000 | $0 | 16,321,248 (Direct) | View |
| 2022-11-01 Tax Withholding | 2022-11-03 4:05 pm | N/A N/A | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 454,856 | $1.6 | 17,445,480 (Direct) | View |
| 2022-09-26 Option Award | 2022-09-28 4:06 pm | N/A N/A | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 3,600,000 | $0 | 17,913,496 (Direct) | View |
| 2022-08-01 Tax Withholding | 2022-08-03 4:10 pm | N/A N/A | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 454,856 | $0.6725 | 14,913,496 (Direct) | View |
| 2022-05-01 Tax Withholding | 2022-05-03 8:18 pm | N/A N/A | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 432,128 | $0.5225 | 15,394,032 (Direct) | View |
| 2022-02-01 Option Award | 2022-02-03 5:54 pm | N/A N/A | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 133,776 | $0.7475 | 15,826,160 (Direct) | View |
| 2022-02-01 Tax Withholding | 2022-02-03 5:54 pm | N/A N/A | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 288,320 | $0.7762 | 15,826,160 (Direct) | View |
Ownership | 2021-11-18 6:07 pm | N/A N/A | ALSP Orchid Acquisition Corp I | ALOR | Hahn Mark W Director | 0 | $0 | 0 (Direct) | View |
| 2021-11-01 Tax Withholding | 2021-11-03 7:51 pm | N/A N/A | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 454,848 | $0.64 | 15,991,120 (Direct) | View |
| 2021-08-01 Tax Withholding | 2021-08-03 9:45 pm | N/A N/A | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 454,840 | $0.785 | 16,456,384 (Direct) | View |
| 2021-05-03 Tax Withholding | 2021-05-05 4:06 pm | N/A N/A | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 2,122,448 | $0.8875 | 16,921,640 (Direct) | View |
| 2021-01-28 Option Award | 2021-02-01 8:53 pm | N/A N/A | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 105,824 | $0 | 19,081,232 (Direct) | View |
Ownership | 2021-01-04 8:16 pm | N/A N/A | Verona Pharma plc | VRNA | Hahn Mark W Chief Financial Officer | 0 | $0 | 18,975,408 (Direct) | View |
| 2019-11-12 Disposition | 2019-11-12 4:34 pm | N/A 2028-10-07 | Dova Pharmaceuticals Inc. | DOVA | Hahn Mark W Chief Financial Officer | 309,024 | $0 | 0 (Direct) | View |